Lisata Therapeutics, Inc.

Welcome to the La Sada Therapeutics first quarter 2025 financial results and business update conference call. Currently, all participants are in listen-only mode. Following management's prepared remarks, we will hold a Q&A session. To ask a question at that time, please press star 11 on your telephone. You will then hear an automated message advising your hand is raised. As a reminder, this call is being recorded today, Thursday, May 8, 2025. I will now turn the call over to John Mendito, Vice President of Investor Relations and Corporate Communications at La Sada. Please go ahead, sir.

Thank you, operator, and good afternoon, everyone. Welcome to La Sada's first quarter 2025 conference call to discuss our financial results and to provide a business update. Joining me today from our management team are Dr. David Mazzo, President and Chief Executive Officer, Dr. Kristen Buck, Executive Vice President of Research and Development and Chief Medical Officer, and James Nisko, Senior Vice President of Finance and Treasury and Chief Accounting Officer. Shortly before this call, we issued a press release announcing our first quarter 2025 financial results, which is all under the Investors and News section of the company website, along with a webcast replay of this call. If you have not received this news release or would like to be added to the company's email distribution list, please subscribe to the email alerts on the company website or email me at jmendito at lasada.com. to be added to the list. Before we begin, I remind you that comments made by management during this conference call will contain forward-looking statements that involve risks and entities regarding the operations and future results of this audit. I encourage you to review the company's filings with the Securities and Exchange Commission, including, without limitation, its forms 10-Q, 8-K, and 10-K, which identify specific risk factors that may cause actual results or events to differ materially from those described in the forward-looking statements. Furthermore, the content of this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, Thursday, May 8, 2025. Losada Therapeutics undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this conference call. With that, I will now turn the call over to Dr. Mazzo. Dave?

Thank you, John. Good afternoon, everyone. It's a pleasure to be here again to provide an overview of Losada's recent business highlights, discuss our first quarter 2025 financial results, and give an update on the progress of our development programs. Building on an eventful 2024, we've maintained strong momentum into 2025 despite persistent market headwinds for small cap healthcare companies. We continue to make significant progress advancing our clinical development portfolio for our novel product candidate, Certepatide, targeting solid tumors and other difficult-to-treat diseases. The ongoing accumulation of both preclinical data and especially clinical data supports our belief that Certepatide has the potential to become a cornerstone of a revised standard of care treatment regimen for advanced solid tumors of many types. We were particularly encouraged by the preliminary results from both cohort A of the ASCEND trial and the I-LISTED trial data presented at the 2025 ASCO GI Symposium in January. These data reinforced both such appetite potential and our overall development strategy. We anticipate that the next 12 to 18 months will be data rich for LUSADA with several key milestones on the horizon. We will continue to share our progress and key findings as they become available. Following the review of our financial results, Dr. Kristen Buck, our Chief Medical Officer and Head of Research and Development, will provide an update on our ongoing and planned clinical and preclinical programs, including timelines and key objectives. And with that, I will now turn the call over to James Misko, our Senior Vice President of Finance and Treasury and Chief Accounting Officer. James?